Suchergebnisse - "Dagenais, Gilles"

Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study von Dagenais, Gilles R, Leong, Darryl P, Rangarajan, Sumathy, Lanas, Fernando, Lopez-Jaramillo, Patricio, Gupta, Rajeev, Diaz, Rafael, Avezum, Alvaro, Oliveira, Gustavo B F, Wielgosz, Andreas, Parambath, Shameena R, Mony, Prem, Alhabib, Khalid F, Temizhan, Ahmet, Ismail, Noorhassim, Chifamba, Jephat, Yeates, Karen, Khatib, Rasha, Rahman, Omar, Zatonska, Katarzyna, Kazmi, Khawar, Wei, Li, Zhu, Jun, Rosengren, Annika, Vijayakumar, K, Kaur, Manmeet, Mohan, Viswanathan, Yusufali, AfzalHussein, Kelishadi, Roya, Teo, Koon K, Joseph, Philip, Yusuf, Salim

“… To our knowledge, no previous study has prospectively documented the incidence of common diseases and related mortality in high-income countries (HICs), …”
Volltext

Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events von O'Donnell, Martin, Mente, Andrew, Rangarajan, Sumathy, McQueen, Matthew J, Wang, Xingyu, Liu, Lisheng, Yan, Hou, Lee, Shun Fu, Mony, Prem, Devanath, Anitha, Rosengren, Annika, Lopez-Jaramillo, Patricio, Diaz, Rafael, Avezum, Alvaro, Lanas, Fernando, Yusoff, Khalid, Iqbal, Romaina, Ilow, Rafal, Mohammadifard, Noushin, Gulec, Sadi, Yusufali, Afzal Hussein, Kruger, Lanthe, Yusuf, Rita, Chifamba, Jephat, Kabali, Conrad, Dagenais, Gilles, Lear, Scott A, Teo, Koon, Yusuf, Salim

“… In a large study in 17 countries, an estimated sodium intake that was either higher or lower than the average estimated sodium intake was associated with an …”
Volltext

Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study von Yusuf, Salim, Joseph, Philip, Rangarajan, Sumathy, Islam, Shofiqul, Mente, Andrew, Hystad, Perry, Brauer, Michael, Kutty, Vellappillil Raman, Gupta, Rajeev, Wielgosz, Andreas, AlHabib, Khalid F, Dans, Antonio, Lopez-Jaramillo, Patricio, Avezum, Alvaro, Lanas, Fernando, Oguz, Aytekin, Kruger, Iolanthe M, Diaz, Rafael, Yusoff, Khalid, Mony, Prem, Chifamba, Jephat, Yeates, Karen, Kelishadi, Roya, Yusufali, Afzalhussein, Khatib, Rasha, Rahman, Omar, Zatonska, Katarzyna, Iqbal, Romaina, Wei, Li, Bo, Hu, Rosengren, Annika, Kaur, Manmeet, Mohan, Viswanathan, Lear, Scott A, Teo, Koon K, Leong, Darryl, O'Donnell, Martin, McKee, Martin, Dagenais, Gilles

“… Global estimates of the effect of common modifiable risk factors on cardiovascular disease and mortality are largely based on data from separate studies, using …”
Volltext

Polypill with or without Aspirin in Persons without Cardiovascular Disease von Yusuf, Salim, Joseph, Philip, Dans, Antonio, Gao, Peggy, Teo, Koon, Xavier, Denis, López-Jaramillo, Patricio, Yusoff, Khalid, Santoso, Anwar, Gamra, Habib, Talukder, Shamim, Christou, Courtney, Girish, Preeti, Yeates, Karen, Xavier, Freeda, Dagenais, Gilles, Rocha, Catalina, McCready, Tara, Tyrwhitt, Jessica, Bosch, Jackie, Pais, Prem

“… Participants without cardiovascular disease who were at increased risk were randomly assigned to receive a polypill (containing a statin and three …”
Volltext

Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis von Joseph, Philip, Roshandel, Gholamreza, Gao, Peggy, Pais, Prem, Lonn, Eva, Xavier, Denis, Avezum, Alvaro, Zhu, Jun, Liu, Lisheng, Sliwa, Karen, Gamra, Habib, Bangdiwala, Shrikant I, Teo, Koon, Diaz, Rafael, Dans, Antonio, Lopez-Jaramillo, Patricio, Prabhakaran, Dorairaj, Castellano, Jose Maria, Fuster, Valentin, Rodgers, Anthony, Huffman, Mark D, Bosch, Jackie, Dagenais, Gilles R, Malekzadeh, Reza, Yusuf, Salim

“… In randomised controlled trials, fixed-dose combination treatments (or polypills) have been shown to reduce a composite of cardiovascular disease outcomes in …”
Volltext

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease von Eikelboom, John W, Connolly, Stuart J, Bosch, Jackie, Dagenais, Gilles R, Hart, Robert G, Shestakovska, Olga, Diaz, Rafael, Alings, Marco, Lonn, Eva M, Anand, Sonia S, Widimsky, Petr, Hori, Masatsugu, Avezum, Alvaro, Piegas, Leopoldo S, Branch, Kelley R.H, Probstfield, Jeffrey, Bhatt, Deepak L, Zhu, Jun, Liang, Yan, Maggioni, Aldo P, Lopez-Jaramillo, Patricio, O’Donnell, Martin, Kakkar, Ajay K, Fox, Keith A.A, Parkhomenko, Alexander N, Ertl, Georg, Störk, Stefan, Keltai, Matyas, Ryden, Lars, Pogosova, Nana, Dans, Antonio L, Lanas, Fernando, Commerford, Patrick J, Torp-Pedersen, Christian, Guzik, Tomek J, Verhamme, Peter B, Vinereanu, Dragos, Kim, Jae-Hyung, Tonkin, Andrew M, Lewis, Basil S, Felix, Camilo, Yusoff, Khalid, Steg, P. Gabriel, Metsarinne, Kaj P, Cook Bruns, Nancy, Misselwitz, Frank, Chen, Edmond, Leong, Darryl, Yusuf, Salim

“… In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events …”
Volltext

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey von Yusuf, Salim, Islam, Shofiqul, Chow, Clara K, Rangarajan, Sumathy, Dagenais, Gilles, Diaz, Rafael, Gupta, Rajeev, Kelishadi, Roya, Iqbal, Romaina, Avezum, Alvaro, Kruger, Annamarie, Kutty, Raman, Lanas, Fernando, Lisheng, Liu, Wei, Li, Lopez-Jaramillo, Patricio, Oguz, Aytekin, Rahman, Omar, Swidan, Hany, Yusoff, Khalid, Zatonski, Witold, Rosengren, Annika, Teo, Koon K

“… Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention …”
Volltext

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease von Lonn, Eva M, Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Liu, Lisheng, Pais, Prem, Diaz, Rafael, Xavier, Denis, Sliwa, Karen, Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S, Keltai, Katalin, Keltai, Matyas, Chazova, Irina, Peters, Ron J.G, Held, Claes, Yusoff, Khalid, Lewis, Basil S, Jansky, Petr, Parkhomenko, Alexander, Khunti, Kamlesh, Toff, William D, Reid, Christopher M, Varigos, John, Leiter, Lawrence A, Molina, Dora I, McKelvie, Robert, Pogue, Janice, Wilkinson, Joanne, Jung, Hyejung, Dagenais, Gilles, Yusuf, Salim

“… In one comparison from a 2-by-2 factorial trial, over 12,000 participants with a mean baseline blood pressure of 138/82 mm Hg were assigned to candesartan plus …”
Volltext

Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis von Dagenais, Gilles R, Pais, Prem, Gao, Peggy, Roshandel, Gholamreza, Malekzadeh, Reza, Joseph, Philip, Yusuf, Salim

“… ObjectiveTo evaluate the effects of fixed dose combination (FDC) medications on cardiovascular outcomes in different age groups in an individual participant …”
Volltext

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease von Yusuf, Salim, Lonn, Eva, Pais, Prem, Bosch, Jackie, López-Jaramillo, Patricio, Zhu, Jun, Xavier, Denis, Avezum, Alvaro, Leiter, Lawrence A, Piegas, Leopoldo S, Parkhomenko, Alexander, Keltai, Matyas, Keltai, Katalin, Sliwa, Karen, Chazova, Irina, Peters, Ron J.G, Held, Claes, Yusoff, Khalid, Lewis, Basil S, Jansky, Petr, Khunti, Kamlesh, Toff, William D, Reid, Christopher M, Varigos, John, Accini, Jose L, McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Liu, Lisheng, Diaz, Rafael, Dans, Antonio, Dagenais, Gilles

“… In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or …”
Volltext

Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease von Eikelboom, John W, Bhatt, Deepak L, Fox, Keith A A, Bosch, Jacqueline, Connolly, Stuart J, Anand, Sonia S, Avezum, Alvaro, Berkowitz, Scott D, Branch, Kelley R H, Dagenais, Gilles R, Félix, Camilo, Guzik, Tomasz J, Hart, Robert G, Maggioni, Aldo P, Muehlhofer, Eva, Sharma, Mukul, Shestakovska, Olga, Yusuf, Salim

“… The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular …”
Weitere Angaben

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease von Yusuf, Salim, Bosch, Jackie, Dagenais, Gilles, Zhu, Jun, Xavier, Denis, Liu, Lisheng, Pais, Prem, López-Jaramillo, Patricio, Leiter, Lawrence A., Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S., Parkhomenko, Alexander, Keltai, Katalin, Keltai, Matyas, Sliwa, Karen, Peters, Ron J.G., Held, Claes, Chazova, Irina, Yusoff, Khalid, Lewis, Basil S., Jansky, Petr, Khunti, Kamlesh, Toff, William D., Reid, Christopher M., Varigos, John, Sanchez-Vallejo, Gregorio, McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Gao, Peggy, Diaz, Rafael, Lonn, Eva

Volltext

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease von Yusuf, Salim, Bosch, Jackie, Dagenais, Gilles, Zhu, Jun, Xavier, Denis, Liu, Lisheng, Pais, Prem, López-Jaramillo, Patricio, Leiter, Lawrence A, Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S, Parkhomenko, Alexander, Keltai, Katalin, Keltai, Matyas, Sliwa, Karen, Peters, Ron J.G, Held, Claes, Chazova, Irina, Yusoff, Khalid, Lewis, Basil S, Jansky, Petr, Khunti, Kamlesh, Toff, William D, Reid, Christopher M, Varigos, John, Sanchez-Vallejo, Gregorio, McKelvie, Robert, Pogue, Janice, Jung, Hyejung, Gao, Peggy, Diaz, Rafael, Lonn, Eva

“… In one comparison from a 2-by-2 factorial trial, 12,705 persons at intermediate cardiovascular risk were assigned to either rosuvastatin or placebo. At 5.6 …”
Volltext

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials von Dagenais, Gilles R, Pogue, Janice, Fox, Kim, Simoons, Marteen L, Yusuf, Salim

“… Angiotensin-converting-enzyme (ACE) inhibitors reduce cardiovascular mortality and morbidity in patients with heart failure or left ventricular systolic …”
Volltext

Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries von Yusuf, Salim, Rangarajan, Sumathy, Teo, Koon, Islam, Shofiqul, Li, Wei, Liu, Lisheng, Bo, Jian, Lou, Qinglin, Lu, Fanghong, Liu, Tianlu, Yu, Liu, Zhang, Shiying, Mony, Prem, Swaminathan, Sumathi, Mohan, Viswanathan, Gupta, Rajeev, Kumar, Rajesh, Vijayakumar, Krishnapillai, Lear, Scott, Anand, Sonia, Wielgosz, Andreas, Diaz, Rafael, Avezum, Alvaro, Lopez-Jaramillo, Patricio, Lanas, Fernando, Yusoff, Khalid, Ismail, Noorhassim, Iqbal, Romaina, Rahman, Omar, Rosengren, Annika, Yusufali, Afzalhussein, Kelishadi, Roya, Kruger, Annamarie, Puoane, Thandi, Szuba, Andrzej, Chifamba, Jephat, Oguz, Aytekin, McQueen, Matthew, McKee, Martin, Dagenais, Gilles

“… In a large study, cardiac risk-factor burden was correlated with cardiovascular disease and mortality. High-income countries had a high risk burden but low …”
Volltext

Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data von Khatib, Rasha, McKee, Martin, Shannon, Harry, Chow, Clara, Rangarajan, Sumathy, Teo, Koon, Wei, Li, Mony, Prem, Mohan, Viswanathan, Gupta, Rajeev, Kumar, Rajesh, Vijayakumar, Krishnapillai, Lear, Scott A, Diaz, Rafael, Avezum, Alvaro, Lopez-Jaramillo, Patricio, Lanas, Fernando, Yusoff, Khalid, Ismail, Noorhassim, Kazmi, Khawar, Rahman, Omar, Rosengren, Annika, Monsef, Nahed, Kelishadi, Roya, Kruger, Annamarie, Puoane, Thandi, Szuba, Andrzej, Chifamba, Jephat, Temizhan, Ahmet, Dagenais, Gilles, Gafni, Amiram, Yusuf, Salim

“… WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025 …”
Volltext

Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals von Joseph, Philip G, Healey, Jeffrey S, Raina, Parminder, Connolly, Stuart J, Ibrahim, Quazi, Gupta, Rajeev, Avezum, Alvaro, Dans, Antonio L, Lopez-Jaramillo, Patricio, Yeates, Karen, Teo, Koon, Douma, Reuben, Bahonar, Ahmad, Chifamba, Jephat, Lanas, Fernando, Dagenais, Gilles R, Lear, Scott A, Kumar, Rajesh, Kengne, Andre P, Keskinler, Mirac, Mohan, Viswanathan, Mony, Prem, Alhabib, Khalid F, Huisman, Hugo, Iype, Thomas, Zatonska, Katarzyna, Ismail, Rosnah, Kazmi, Khawar, Rosengren, Annika, Rahman, Omar, Yusufali, Afzalhussein, Wei, Li, Orlandini, Andres, Islam, Shofiqul, Rangarajan, Sumathy, Yusuf, Salim

“… To compare the prevalence of electrocardiogram (ECG)-documented atrial fibrillation (or flutter) (AF) across eight regions of the world, and to examine …”
Weitere Angaben

Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study von Smyth, Andrew, Teo, Koon K, Rangarajan, Sumathy, O'Donnell, Martin, Zhang, Xiaohe, Rana, Punam, Leong, Darryl P, Dagenais, Gilles, Seron, Pamela, Rosengren, Annika, Schutte, Aletta E, Lopez-Jaramillo, Patricio, Oguz, Ayetkin, Chifamba, Jephat, Diaz, Rafael, Lear, Scott, Avezum, Alvaro, Kumar, Rajesh, Mohan, Viswanathan, Szuba, Andrzej, Wei, Li, Yang, Wang, Jian, Bo, McKee, Martin, Yusuf, Salim

“… Alcohol consumption is proposed to be the third most important modifiable risk factor for death and disability. However, alcohol consumption has been …”
Volltext

Psychosocial Stressors at Work and Coronary Heart Disease Risk in Men and Women: 18-Year Prospective Cohort Study of Combined Exposures von Lavigne-Robichaud, Mathilde, Trudel, Xavier, Talbot, Denis, Milot, Alain, Gilbert-Ouimet, Mahée, Vézina, Michel, Laurin, Danielle, Dionne, Clermont E, Pearce, Neil, Dagenais, Gilles R, Brisson, Chantal

“… Psychosocial stressors at work, like job strain and effort-reward imbalance (ERI), can increase coronary heart disease (CHD) risk. ERI indicates an imbalance …”
Weitere Angaben

Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin von Eikelboom, John W, Bosch, Jacqueline J, Connolly, Stuart J, Shestakovska, Olga, Dagenais, Gilles R, Hart, Robert G, Leong, Darryl P, O'Donnell, Martin, Fox, Keith A A, Bhatt, Deepak L, Cairns, John A, Tasto, Christoph, Berkowitz, Scott D, Cook Bruns, Nancy, Muehlhofer, Eva, Diaz, Rafael, Maggioni, Aldo P, Yusuf, Salim

“… In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin …”
Weitere Angaben